Enliven Therapeutics(US:ELVN)2026-03-03 21:10Financial Performance - Enliven Therapeutics reported a net loss of $29.7 million for Q4 2025, compared to a net loss of $23.2 million in Q4 2024, with a total net loss of $103.7 million for the full year 2025, up from $89.0 million in 2024[7]. - Enliven's total operating expenses for the full year 2025 were $119.7 million, compared to $104.6 million in 2024[14]. Cash Position - The company had cash, cash equivalents, and marketable securities totaling $462.6 million as of December 31, 2025, providing a cash runway into the first half of 2029[6]. Research and Development - Research and development (R&D) expenses for Q4 2025 were $21.2 million, compared to $20.7 million in Q4 2024, while full-year R&D expenses increased to $85.9 million from $80.8 million[6]. - The company plans to initiate the Phase 3 ENABLE-2 trial of ELVN-001 in the second half of 2026, following key regulatory interactions and data readouts throughout 2026[1]. Clinical Trials - Enliven announced positive initial Phase 1b data for ELVN-001, with a cumulative major molecular response (MMR) rate of 47% in the 80 mg QD cohort and 69% in the 60/120 mg QD cohort[4]. - As of December 22, 2025, 60 patients were enrolled in the Phase 1b trial, with 53% having received four or more prior TKIs, indicating a heavily pretreated patient population[6]. - The company achieved a maintained MMR rate of 100% in both cohorts of patients who achieved MMR[4]. Administrative Expenses - General and administrative (G&A) expenses for Q4 2025 were $13.0 million, significantly higher than $6.2 million in Q4 2024, primarily due to stock-based compensation related to the CEO transition[6]. Strategic Focus - The company is focused on demonstrating ELVN-001's potential as a best-in-class ATP-competitive inhibitor for CML patients[2].